Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells

Abstract

Ac-Phe-Lys-PABC-DOX (PDOX) is a smart doxorubicin (DOX) prodrug designed to decrease toxicities while maintaining the potent anticancer effects of DOX. This study was aimed at elucidating the effectiveness and toxicities of DOX and PDOX in patient-derived MCF-7 breast cancer cells in vitro. The MCF-7 cells were exposed to both PDOX and DOX, and cytotoxicities, cell cycle and P53/P21 signaling alterations were studied. Abundant cathepsin B was found in the MCF-7 cells, and treatment with PDOX and DOX triggered dose- and time-dependent cytotoxicity and resulted in a significant reduction in cell viability. The IC₅₀ of PDOX and DOX was 3.91 and 0.94 μmol/L, respectively. Both PDOX and DOX caused an up-regulation of the P53/P21-related signal pathway, and PDOX significantly increased expression of P53 and caspase 3, and arrested the cell cycle at the G₁/G₂ phase. As compared with DOX, PDOX reduced toxicities, and it may have different action mechanisms on breast cancer cells.

Keywords

breast cancer / doxorubicin / prodrug / molecular targeted therapy / cathepsin B

References

[1] SleemanJ, SteegPS. Cancer metastasis as a therapeutic target. Euro J Cancer, 2010, 46(7): 1177-1180

[2] JemalA, BrayF, CenterMM, et al.. Global cancer statistics. Ca Cancer J Clin, 201169-90

[3] GronerB, WeissA. Targeting survivin in cancer: novel drug development approaches. Bio Drugs, 2014, 28(1): 27-39

[4] FerreiraAL, MatsubaraLS, MatsubaraBB. Anthracyclineinduced cardiotoxicity. Cardiovasc Hematol Agents Med Chem, 2008, 6(4): 278-281

[5] SawyerDB. Anthracyclines and heart failure. N Engl J Med, 2013, 368(12): 1154-1156

[6] TurkV, StokaV, VasiljevaO, et al.. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta, 2012, 1824(1): 68-88

[7] RothbergJM, BaileyKM, WojtkowiakJW, et al.. Acidmediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia, 2013, 15(10): 1125-1137

[8] RaghavN, SinghM. Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H. Eur J Pharm Sci, 2014, 54(1): 28-39

[9] DubowchikGM, FirestoneRA. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requrements for efficient release of doxorubicin. Bioorg Med Chem, 1998, 8(23): 3341-3346

[10] DubowchikGM, MosureK, KnipeJO, et al.. Cathepsin B-sensitve dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (taxol), mitomycin c and doxorubicin. Bioorgan Med Chem, 1998, 8(23): 3347-3352

[11] DubowchikGM, FirestoneRA, PadillaL, et al.. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem, 2002, 13(4): 855-869

[12] ShaoLH, LiuSP, HouJX, et al.. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer, 2012, 118(11): 2986-2996

[13] WangQ, ZhongYJ, YuanJP, et al.. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med, 2013, 11(1): 192

[14] PengC, LiuXL, ChenC, et al.. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials, 2011, 32(11): 2907-2917

[15] MeyerHJ, WilkeH. Treatment strategies in gastric cancer. Dtsch Arztebl Int, 2011, 108(41): 698-705

[16] BangYJ, Van CutsemE, FeyerislovaA, et al.. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697

[17] ScottAM, LeeFT, JonesR, et al.. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res, 2005, 11(13): 4810-4817

[18] HanakiH, YamamotoH, SakaneH, et al.. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther, 2012, 11(2): 298-307

[19] SchmidB, ChungDE, WarneckeA, et al.. Albuminbinding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem, 2007, 18(3): 702-716

[20] KawajiriH, YashiroM, ShintoO, et al.. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res, 2008, 14(9): 2850-2860

[21] HuynhH, ChowPK, SooKC. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther, 2007, 6(9): 2468-2476

[22] YangS, NqoVC, LewGB, et al.. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther, 2009, 8(9): 2537-2545

[23] LebrechtD, GeistA, KetelsenUP, et al.. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer, 2007, 120(4): 927-934

[24] KratzF, FichtnerI, GraeserR. Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Invest New Drugs, 2012, 30(4): 1743-1749

[25] UngerC, HaringB, MedingerM, et al.. Phase I and pharmacokinetic study of the^(6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin Cancer Res, 2007, 13(16): 4858-4866

[26] ChenQ, FeiJ, WuL, et al.. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett, 2011, 2(4): 693-699

[27] Abu AjajK, GraeserR, FichtnerI, et al.. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol, 2009, 64(2): 413-418

[28] SchallyAV, NaqyA. Cancer chemotherapy based on targeting of cytotoxic peptide. Eur J Endocrinol, 1999, 141(1): 1-14

[29] CummingsJ, McArdleCS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer, 1986, 53(6): 835-838

[30] ShuklaA, HillegassJM, MacPhersonMB, et al.. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer, 2010, 9: 314

[31] CagnolS, ChambardJC. ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence. FEBS J, 2010, 277(1): 2-21

[32] OkumuraT. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol, 2010, 45(11): 1097-1102

[33] PritchardAL, HaywardNK. Molecular pathways: mitogenactivated protein kinase pathway mutations and drug resistance. Clin Cancer Res, 2013, 19(9): 2301-2319

[34] ZhongY, LiuSP, FirestoneRA, et al.. Anticancer effects of Ac-Phe-Lys-PABC-doxorubicin via mitochondria-centered apoptosis involving reactive oxidative stress and the ERK1/2 signaling pathway in MGC-803 cells. Oncol Rep, 2013, 30(4): 1681-1686